An Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions

Aslı       Gelincik; Ozlem       Cavkaytar; Semanur      Kuyucu
doi:10.2174/1381612825666191106115556
Abstract

Severe cutaneous drug hypersensitivity reactions involve of different mechanisms , some of which are life-threatening, such as Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, generalized bullous fixed drug eruptions, serum sickness and serum sickness-like reaction and drug-induced vasculitis. These reactions may have substantial morbidity and mortality. In the past years, successive studies have provided new evidence regarding the pathogenesis of some of these severe reactions and revealed that underlying mechanisms are highly variable. Since these reactions have unique presentations and distinct pathomechanisms, the treatment methods and response rates might be different among various entities. Although supportive and local therapies are sufficient in some of these reactions, targeted immunosuppressive treatments and even mechanistic therapies such as plasmapheresis may be required in severe ones. However, there is still insufficient evidence to support the best treatment options for these patients since number of patients and large-scale studies are limited. In this review, conventional and new treatment options for severe cutaneous drug hypersensitivity reactions are presented in detail in order to provide the contemporary approaches to lessen the morbidity and mortality relevant to these severe iatrogenic diseases.
Keywords: Severe cutaneous drug hypersensitivity, Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, generalized bullous fixed drug eruptions, serum sickness and serum sickness-like reaction, drug-induced vasculitis, management, corticosteroids, intravenous immunoglobulin, treatment.
« Previous
[1] 
Brockow K, Ardern-Jones MR, Mockenhaupt M, et al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy  2019; 74(1): 14-27.
[http://dx.doi.org/10.1111/all.13562] [PMID:  30028512] 
[2] 
Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges  2009; 7(2): 142-60.
[http://dx.doi.org/10.1111/j.1610-0387.2008.06878.x] [PMID:  19371237] 
[3] 
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther  1981; 30(2): 239-45.
[http://dx.doi.org/10.1038/clpt.1981.154] [PMID:  7249508] 
[4] 
Arimone Y, Bidault I, Dutertre JP, et al. Updating the french method for the causality assessment of adverse drug reactions. Therapie  2013; 68(2): 69-76.
[http://dx.doi.org/10.2515/therapie/2013016] [PMID:  23773347] 
[5] 
Agbabiaka TB, Savović J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf  2008; 31(1): 21-37.
[http://dx.doi.org/10.2165/00002018-200831010-00003] [PMID:  18095744] 
[6] 
Paulmann M, Mockenhaupt M. Severe drug hypersensitivity reactions: clinical pattern, diagnosis, etiology and therapeutic options. Curr Pharm Des  2016; 22(45): 6852-61.
[http://dx.doi.org/10.2174/1381612822666160928125152] [PMID:  27779083] 
[7] 
Cho YT, Yang CW, Chu CY. Drug reaction with eosinophilia and systemic symptoms (DRESS): an interplay among drugs, viruses, and immune system. Int J Mol Sci  2017; 18(6)e1243
[http://dx.doi.org/10.3390/ijms18061243] [PMID:  28598363] 
[8] 
Ramasamy SN, Korb-Wells CS, Kannangara DR, et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf  2013; 36(10): 953-80.
[http://dx.doi.org/10.1007/s40264-013-0084-0] [PMID:  23873481] 
[9] 
Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol  2013; 169(5): 1071-80.
[http://dx.doi.org/10.1111/bjd.12501] [PMID:  23855313] 
[10] 
Trubiano JA, Aung AK, Nguyen M, et al. A comparative analysis between antibiotic- and nonantibiotic-associated delayed cutaneous adverse drug reactions. J Allergy Clin Immunol Pract  2016; 4(6): 1187-93.
[http://dx.doi.org/10.1016/j.jaip.2016.04.026] [PMID:  27283055] 
[11] 
Busto U, Naranjo CA, Sellers EM. Comparison of two recently published algorithms for assessing the probability of adverse drug reactions. Br J Clin Pharmacol  1982; 13(2): 223-7.
[http://dx.doi.org/10.1111/j.1365-2125.1982.tb01361.x] [PMID:  7059419] 
[12] 
Adler NR, Aung AK, Ergen EN, Trubiano J, Goh MSY, Phillips EJ. Recent advances in the understanding of severe cutaneous adverse reactions. Br J Dermatol  2017; 177(5): 1234-47.
[http://dx.doi.org/10.1111/bjd.15423] [PMID:  28256714] 
[13] 
Romano A, Pettinato R, Andriolo M, et al. Hypersensitivity to aromatic anticonvulsants: in vivo and in vitro cross-reactivity studies. Curr Pharm Des  2006; 12(26): 3373-81.
[http://dx.doi.org/10.2174/138161206778193962] [PMID:  17017931] 
[14] 
Lin CY, Wang CW, Hui CR, et al. Delayed-type hypersensitivity reactions induced by proton pump inhibitors: a clinical and in vitro T-cell reactivity study. Allergy  2018; 73(1): 221-9.
[http://dx.doi.org/10.1111/all.13235] [PMID:  28658503] 
[15] 
Miyazu D, Kodama N, Yamashita D, et al. DRESS syndrome caused by cross-reactivity between vancomycin and subsequent teicoplanin administration: a case report. Am J Case Rep  2016; 17: 625-31.
[http://dx.doi.org/10.12659/AJCR.899149] [PMID:  27572807] 
[16] 
Pichler WJ, Daubner B, Kawabata T. Drug hypersensitivity: flare-up reactions, cross-reactivity and multiple drug hypersensitivity. J Dermatol  2011; 38(3): 216-21.
[http://dx.doi.org/10.1111/j.1346-8138.2010.01142.x] [PMID:  21342222] 
[17] 
Romano A, Valluzzi RL, Caruso C, Maggioletti M, Gaeta F. Non-immediate cutaneous reactions to beta-lactams: approach to diagnosis. Curr Allergy Asthma Rep  2017; 17(4): 23.
[http://dx.doi.org/10.1007/s11882-017-0691-4] [PMID:  28382604] 
[18] 
Trubiano J, Phillips E. Antimicrobial stewardship’s new weapon? a review of antibiotic allergy and pathways to ‘de-labeling’. Curr Opin Infect Dis  2013; 26(6): 526-37.
[http://dx.doi.org/10.1097/QCO.0000000000000006] [PMID:  24126717] 
[19] 
Romano A, Gaeta F, Valluzzi RL, Maggioletti M, Caruso C, Quaratino D. Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell-mediated hypersensitivity to penicillins. J Allergy Clin Immunol  2016; 138(1): 179-86.
[http://dx.doi.org/10.1016/j.jaci.2016.01.025] [PMID:  27016799] 
[20] 
Buonomo A, Nucera E, Pecora V, et al. Cross-reactivity and tolerability of cephalosporins in patients with cell-mediated allergy to penicillins. J Investig Allergol Clin Immunol  2014; 24(5): 331-7.
[PMID:  25345303] 
[21] 
Torres MJ, Blanca M. The complex clinical picture of beta-lactam hypersensitivity: penicillins, cephalosporins, monobactams, carbapenems, and clavams. Med Clin North Am  2010; 94(4): 805-20. [xii].
[http://dx.doi.org/10.1016/j.mcna.2010.04.006] [PMID: 20609864] 
[22] 
El-Ghaiesh S, Monshi MM, Whitaker P, et al. Characterization of the antigen specificity of T-cell clones from piperacillin-hypersensitive patients with cystic fibrosis. J Pharmacol Exp Ther  2012; 341(3): 597-610.
[http://dx.doi.org/10.1124/jpet.111.190900] [PMID:  22371438] 
[23] 
Romano A, Gaeta F, Valluzzi RL, et al. Absence of cross-reactivity to carbapenems in patients with delayed hypersensitivity to penicillins. Allergy  2013; 68(12): 1618-21.
[http://dx.doi.org/10.1111/all.12299] [PMID:  24180646] 
[24] 
Romano A, Viola M, Guéant-Rodriguez RM, Gaeta F, Pettinato R, Guéant JL. Imipenem in patients with immediate hypersensitivity to penicillins. N Engl J Med  2006; 354(26): 2835-7.
[http://dx.doi.org/10.1056/NEJMc053529] [PMID:  16807429] 
[25] 
Atanasković-Marković M, Gaeta F, Medjo B, Viola M, Nestorović B, Romano A. Tolerability of meropenem in children with IgE-mediated hypersensitivity to penicillins. Allergy  2008; 63(2): 237-40.
[http://dx.doi.org/10.1111/j.1398-9995.2007.01532.x] [PMID:  18186815] 
[26] 
Schiavino D, Nucera E, Lombardo C, et al. Cross-reactivity and tolerability of imipenem in patients with delayed-type, cell-mediated hypersensitivity to beta-lactams. Allergy  2009; 64(11): 1644-8.
[http://dx.doi.org/10.1111/j.1398-9995.2009.02058.x] [PMID:  19392998] 
[27] 
Buonomo A, Nucera E, De Pasquale T, et al. Tolerability of aztreonam in patients with cell-mediated allergy to β-lactams. Int Arch Allergy Immunol  2011; 155(2): 155-9.
[http://dx.doi.org/10.1159/000318844] [PMID:  21196760] 
[28] 
Krivoy N, Taer M, Neuman MG. Antiepileptic drug-induced hypersensitivity syndrome reactions. Curr Drug Saf  2006; 1(3): 289-99.
[http://dx.doi.org/10.2174/157488606777934459] [PMID:  18690940] 
[29] 
Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA  2014; 312(5): 525-34.
[http://dx.doi.org/10.1001/jama.2014.7859] [PMID:  25096692] 
[30] 
Sierra NM, García B, Marco J, Plaza S, Hidalgo F, Bermejo T. Cross hypersensitivity syndrome between phenytoin and carbamazepine. Pharm World Sci  2005; 27(3): 170-4.
[http://dx.doi.org/10.1007/s11096-004-1736-z] [PMID:  16096883] 
[31] 
Wang XQ, Lang SY, Shi XB, Tian HJ, Wang RF, Yang F. Cross-reactivity of skin rashes with current antiepileptic drugs in Chinese population. Seizure  2010; 19(9): 562-6.
[http://dx.doi.org/10.1016/j.seizure.2010.09.003] [PMID:  20888266] 
[32] 
Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia  2007; 48(5): 1015-8.
[http://dx.doi.org/10.1111/j.1528-1167.2007.01022.x] [PMID:  17509004] 
[33] 
Kuyucu S, Caubet JC. Hypersensitivity reactions to antiepileptic drugs in children: epidemiologic, pathogenetic, clinical, and diagnostic aspects. J Allergy Clin Immunol Pract  2018; 6(6): 1879-91.
[34] 
Alvestad S, Lydersen S, Brodtkorb E. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs. Epilepsy Res  2008; 80(2-3): 194-200.
[http://dx.doi.org/10.1016/j.eplepsyres.2008.04.003] [PMID:  18490142] 
[35] 
De Luca F, Losappio LM, Mirone C, et al. Tolerated drugs in subjects with severe cutaneous adverse reactions (SCARs) induced by anticonvulsants and review of the literature. Clin Mol Allergy  2017; 15: 16.
[http://dx.doi.org/10.1186/s12948-017-0072-5] [PMID:  29026345] 
[36] 
Picard D, Vellar M, Janela B, Roussel A, Joly P, Musette P. Recurrence of drug-induced reactions in DRESS patients. J Eur Acad Dermatol Venereol  2015; 29(4): 801-4.
[http://dx.doi.org/10.1111/jdv.12419] [PMID:  24628777] 
[37] 
Studer M, Waton J, Bursztejn AC, Aimone-Gastin I, Schmutz JL, Barbaud A. [Does hypersensitivity to multiple drugs really exist? Ann Dermatol Venereol  2012; 139(5): 375-80.
[http://dx.doi.org/10.1016/j.annder.2012.03.017] [PMID:  22578342] 
[38] 
Mardivirin L, Valeyrie-Allanore L, Branlant-Redon E, et al. Amoxicillin-induced flare in patients with DRESS (Drug reaction with eosinophilia and systemic symptoms): report of seven cases and demonstration of a direct effect of amoxicillin on human herpesvirus 6 replication in vitro. Eur J Dermatol  2010; 20(1): 68-73.
[http://dx.doi.org/10.1684/ejd.2010.0821] [PMID:  19822481] 
[39] 
Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int  2006; 55(1): 1-8.
[http://dx.doi.org/10.2332/allergolint.55.1] [PMID:  17075280] 
[40] 
Pichler WJ, Srinoulprasert Y, Yun J, Hausmann O. Multiple drug hypersensitivity. Int Arch Allergy Immunol  2017; 172(3): 129-38.
[http://dx.doi.org/10.1159/000458725] [PMID:  28315874] 
[41] 
Daubner B, Groux-Keller M, Hausmann OV, et al. Multiple drug hypersensitivity: normal Treg cell function but enhanced in vivo activation of drug-specific T cells. Allergy  2012; 67(1): 58-66.
[http://dx.doi.org/10.1111/j.1398-9995.2011.02720.x] [PMID:  21933197] 
[42] 
Beeler A, Engler O, Gerber BO, Pichler WJ. Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. J Allergy Clin Immunol  2006; 117(2): 455-62.
[http://dx.doi.org/10.1016/j.jaci.2005.10.030] [PMID:  16461148] 
[43] 
Lin YF, Yang CH, Sindy H, et al. Severe cutaneous adverse reactions related to systemic antibiotics. Clin Infect Dis  2014; 58(10): 1377-85.
[http://dx.doi.org/10.1093/cid/ciu126] [PMID:  24599767] 
[44] 
Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part I. clinical perspectives. J Am Acad Dermatol  2013; 68(5): 693-1.
[45] 
Peter JG, Lehloenya R, Dlamini S, et al. Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice. J Allergy Clin Immunol Pract  2017; 5(3): 547-63.
[http://dx.doi.org/10.1016/j.jaip.2017.01.025] [PMID:  28483310] 
[46] 
Uhara H, Saiki M, Kawachi S, Ashida A, Oguchi S, Okuyama R. Clinical course of drug-induced hypersensitivity syndrome treated without systemic corticosteroids. J Eur Acad Dermatol Venereol  2013; 27(6): 722-6.
[http://dx.doi.org/10.1111/j.1468-3083.2012.04547.x] [PMID:  22540194] 
[47] 
Ushigome Y, Kano Y, Ishida T, Hirahara K, Shiohara T. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol  2013; 68(5): 721-8.
[http://dx.doi.org/10.1016/j.jaad.2012.10.017] [PMID:  23182063] 
[48] 
Descamps V, Ben Saïd B, Sassolas B, et al. [Management of drug reaction with eosinophilia and systemic symptoms (DRESS) Ann Dermatol Venereol  2010; 137(11): 703-8.
[http://dx.doi.org/10.1016/j.annder.2010.04.024] [PMID:  21074653] 
[49] 
Wu X, Yang F, Chen S, et al. Clinical, viral and genetic characteristics of drug reaction with eosinophilia and systemic symptoms (DRESS) in shanghai, china. Acta Derm Venereol  2018; 98(4): 401-5.
[http://dx.doi.org/10.2340/00015555-2867] [PMID:  29242946] 
[50] 
Shiohara T, Kano Y. Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management. Expert Opin Drug Saf  2017; 16(2): 139-47.
[PMID:  27936971] 
[51] 
Shiohara T, Kurata M, Mizukawa Y, Kano Y. Recognition of immune reconstitution syndrome necessary for better management of patients with severe drug eruptions and those under immunosuppressive therapy. Allergol Int  2010; 59(4): 333-43.
[http://dx.doi.org/10.2332/allergolint.10-RAI-0260] [PMID:  20962568] 
[52] 
Sueki H, Mizukawa Y, Aoyama Y. Immune reconstitution inflammatory syndrome in non-HIV immunosuppressed patients. J Dermatol  2018; 45(1): 3-9.
[http://dx.doi.org/10.1111/1346-8138.14074] [PMID:  28944502] 
[53] 
Funck-Brentano E, Duong TA, Bouvresse S, et al. Therapeutic management of DRESS: a retrospective study of 38 cases. J Am Acad Dermatol  2015; 72(2): 246-52.
[http://dx.doi.org/10.1016/j.jaad.2014.10.032] [PMID:  25592341] 
[54] 
Kocaoglu C, Cilasun C, Solak ES, Kurtipek GS, Arslan S. Successful treatment of antiepileptic drug-induced DRESS syndrome with pulse methylprednisolone. Case Rep Pediatr  2013; 2013928910
[http://dx.doi.org/10.1155/2013/928910] [PMID:  23691411] 
[55] 
Natkunarajah J, Goolamali S, Craythorne E, et al. Ten cases of drug reaction with eosinophilia and systemic symptoms (DRESS) treated with pulsed intravenous methylprednisolone. Eur J Dermatol  2011; 21(3): 385-91.
[http://dx.doi.org/10.1684/ejd.2011.1300] [PMID:  21527371] 
[56] 
Kano Y, Hiraharas K, Sakuma K, Shiohara T. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol  2006; 155(2): 301-6.
[http://dx.doi.org/10.1111/j.1365-2133.2006.07238.x] [PMID:  16882166] 
[57] 
Kano Y, Sakuma K, Shiohara T. Sclerodermoid graft-versus-host disease-like lesions occurring after drug-induced hypersensitivity syndrome. Br J Dermatol  2007; 156(5): 1061-3.
[http://dx.doi.org/10.1111/j.1365-2133.2007.07784.x] [PMID:  17381460] 
[58] 
Morita C, Yanase T, Shiohara T, Aoyama Y.  Aggressive treatment
in paediatric or young patients with drug-induced hypersensitivity
syndrome (DiHS)/drug reaction with eosinophilia and systemic
symptoms (DRESS) is associated with future development of type
III polyglandular autoimmune syndrome. BMJ Case Rep 2018;
2018: pii: bcr-2018-225528.
[59] 
Ishida T, Kano Y, Mizukawa Y, Shiohara T. The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome. Allergy  2014; 69(6): 798-805.
[http://dx.doi.org/10.1111/all.12410] [PMID:  24749495] 
[60] 
Asano Y, Kagawa H, Kano Y, Shiohara T. Cytomegalovirus disease during severe drug eruptions: report of 2 cases and retrospective study of 18 patients with drug-induced hypersensitivity syndrome. Arch Dermatol  2009; 145(9): 1030-6.
[http://dx.doi.org/10.1001/archdermatol.2009.195] [PMID:  19770444] 
[61] 
Hase I, Arakawa H, Sakuma H, et al. Bronchoscopic investigation of atypical drug-induced hypersensitivity syndrome showing viral lung involvement. Intern Med  2016; 55(18): 2691-6.
[http://dx.doi.org/10.2169/internalmedicine.55.6347] [PMID:  27629969] 
[62] 
Chow ML, Kim D, Kamath S, Peng D, Luu M. Use of antiviral medications in drug reaction with eosinophilia and systemic symptoms (DRESS): a case of infantile DRESS. Pediatr Dermatol  2018; 35(2): e114-6.
[http://dx.doi.org/10.1111/pde.13408] [PMID:  29334124] 
[63] 
Mizukawa Y, Hirahara K, Kano Y, Shiohara T. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms severity score: a useful tool for assessing disease severity and predicting fatal cytomegalovirus disease. J Am Acad Dermatol  2019; 80(3): 670-8.
[64] 
Moling O, Tappeiner L, Piccin A, et al. Treatment of DIHS/DRESS syndrome with combined N-acetylcysteine, prednisone and valganciclovir-a hypothesis. Med Sci Monit  2012; 18(7): CS57-62.
[http://dx.doi.org/10.12659/MSM.883198] [PMID:  22739739] 
[65] 
Kano Y, Inaoka M, Sakuma K, Shiohara T. Virus reactivation and intravenous immunoglobulin (IVIG) therapy of drug-induced hypersensitivity syndrome. Toxicology  2005; 209(2): 165-7.
[http://dx.doi.org/10.1016/j.tox.2004.12.013] [PMID:  15767030] 
[66] 
Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency committee of the american academy of allergy, asthma and immunology. J Allergy Clin Immunol  2006; 117(4)(Suppl.): S525-53.
[http://dx.doi.org/10.1016/j.jaci.2006.01.015] [PMID:  16580469] 
[67] 
Kito Y, Ito T, Tokura Y, Hashizume H. High-dose intravenous immunoglobulin monotherapy for drug-induced hypersensitivity syndrome. Acta Derm Venereol  2012; 92(1): 100-1.
[http://dx.doi.org/10.2340/00015555-1168] [PMID:  21681351] 
[68] 
Galvão VR, Aun MV, Kalil J, Castells M, Giavina-Bianchi P. Clinical and laboratory improvement after intravenous immunoglobulin in drug reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol Pract  2014; 2(1): 107-10.
[http://dx.doi.org/10.1016/j.jaip.2013.11.008] [PMID:  24565781] 
[69] 
Singer EM, Wanat KA, Rosenbach MA. A case of recalcitrant DRESS syndrome with multiple autoimmune sequelae treated with intravenous immunoglobulins. JAMA Dermatol  2013; 149(4): 494-5.
[http://dx.doi.org/10.1001/jamadermatol.2013.1949] [PMID:  23715168] 
[70] 
Santos RP, Ramilo O, Barton T. Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection. Pediatr Infect Dis J  2007; 26(11): 1053-6.
[http://dx.doi.org/10.1097/INF.0b013e318125655d] [PMID:  17984815] 
[71] 
Fields KS, Petersen MJ, Chiao E, Tristani-Firouzi P. Case reports: treatment of nevirapine-associated dress syndrome with intravenous immune globulin (IVIG). J Drugs Dermatol  2005; 4(4): 510-3.
[PMID:  16004028] 
[72] 
Joly P, Janela B, Tetart F, et al. Poor benefit/risk balance of intravenous immunoglobulins in DRESS. Arch Dermatol  2012; 148(4): 543-4.
[http://dx.doi.org/10.1001/archderm.148.4.dlt120002-c] [PMID:  22508885] 
[73] 
Oh HL, Kang DY, Kang HR, et al. Severe cutaneous adverse reactions in korean pediatric patients: a study from the korea SCAR registry. Allergy Asthma Immunol Res  2019; 11(2): 241-53.
[http://dx.doi.org/10.4168/aair.2019.11.2.241] [PMID:  30661316] 
[74] 
Marcus N, Smuel K, Almog M, et al. Successful intravenous immunoglobulin treatment in pediatric severe DRESS syndrome. J Allergy Clin Immunol Pract  2018; 6(4): 1238-42.
[http://dx.doi.org/10.1016/j.jaip.2017.10.016] [PMID:  29198698] 
[75] 
Harman KE, Morris SD, Higgins EM. Persistent anticonvulsant hypersensitivity syndrome responding to ciclosporin. Clin Exp Dermatol  2003; 28(4): 364-5.
[http://dx.doi.org/10.1046/j.1365-2230.2003.01267.x] [PMID:  12823292] 
[76] 
Zuliani E, Zwahlen H, Gilliet F, Marone C. Vancomycin-induced hypersensitivity reaction with acute renal failure: resolution following cyclosporine treatment. Clin Nephrol  2005; 64(2): 155-8.
[http://dx.doi.org/10.5414/CNP64155] [PMID:  16114793] 
[77] 
Lee JH, Park HK, Heo J, et al. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs. J Korean Med Sci  2008; 23(3): 521-5.
[http://dx.doi.org/10.3346/jkms.2008.23.3.521] [PMID:  18583892] 
[78] 
Bourgeois GP, Cafardi JA, Groysman V, Hughey LC. A review of DRESS-associated myocarditis. J Am Acad Dermatol  2012; 66(6): e229-36.
[http://dx.doi.org/10.1016/j.jaad.2010.11.057] [PMID:  21658796] 
[79] 
Daoulah A, Alqahtani AA, Ocheltree SR, Alhabib A, Ocheltree AR.  Acute myocardial infarction in a 56-year-old female patient
treated with sulfasalazine. Am J Emerg Med 2012; 30(4): 638-
e631-633.
[80] 
Bourgeois GP, Cafardi JA, Groysman V, et al. Fulminant myocarditis as a late sequela of DRESS: two cases. J Am Acad Dermatol  2011; 65(4): 889-90.
[http://dx.doi.org/10.1016/j.jaad.2010.12.013] [PMID:  21920256] 
[81] 
Mortezavi M, Lomas J, Looner R. Treatment of drug reaction with eosinophilia and systemic symptoms (DRESS) with mycophenolate mofetil as a steroid sparing agent (abstract). Ann Allergy Asthma Immunol  2014; 113(5)(Suppl.): A29.
[82] 
Shaughnessy KK, Bouchard SM, Mohr MR, Herre JM, Salkey KS. Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis. J Am Acad Dermatol  2010; 62(2): 315-8.
[http://dx.doi.org/10.1016/j.jaad.2009.05.046] [PMID:  19665822] 
[83] 
Laban E, Hainaut-Wierzbicka E, Pourreau F, et al. Cyclophosphamide therapy for corticoresistant drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a patient with severe kidney and eye involvement and epstein-barr virus reactivation. Am J Kidney Dis  2010; 55(3): e11-4.
[http://dx.doi.org/10.1053/j.ajkd.2009.10.054] [PMID:  20110143] 
[84] 
Ziment I. Acetylcysteine: a drug that is much more than a mucokinetic. Biomed Pharmacother  1988; 42(8): 513-9.
[PMID:  3066412] 
[85] 
James LP, Mayeux PR, Hinson JA. Acetaminophen-induced hepatotoxicity. Drug Metab Dispos  2003; 31(12): 1499-506.
[http://dx.doi.org/10.1124/dmd.31.12.1499] [PMID:  14625346] 
[86] 
Agustí AG, Togores B, Ibañez J, et al. Effects of N-acetylcysteine on tissue oxygenation in patients with multiple organ failure and evidence of tissue hypoxia. Eur Respir J  1997; 10(9): 1962-6.
[http://dx.doi.org/10.1183/09031936.97.10091962] [PMID:  9311486] 
[87] 
Ben-Ari Z, Vaknin H, Tur-Kaspa R. N-acetylcysteine in acute hepatic failure (non-paracetamol-induced). Hepatogastroenterology  2000; 47(33): 786-9.
[PMID:  10919033] 
[88] 
Bergamini S, Rota C, Canali R, et al. N-acetylcysteine inhibits in vivo nitric oxide production by inducible nitric oxide synthase. Nitric Oxide  2001; 5(4): 349-60.
[http://dx.doi.org/10.1006/niox.2001.0356] [PMID:  11485373] 
[89] 
Rota C, Bergamini S, Daneri F, Tomasi A, Virgili F, Iannone A. N-Acetylcysteine negatively modulates nitric oxide production in endotoxin-treated rats through inhibition of NF-kappaB activation. Antioxid Redox Signal  2002; 4(1): 221-6.
[http://dx.doi.org/10.1089/152308602753625988] [PMID:  11970856] 
[90] 
Cumbo-Nacheli G, Weinberger J, Alkhalil M, Thati N, Baptist AP. Anticonvulsant hypersensitivity syndrome: is there a role for immunomodulation? Epilepsia  2008; 49(12): 2108-12.
[http://dx.doi.org/10.1111/j.1528-1167.2008.01720.x] [PMID:  18637830] 
[91] 
Redondo P, de Felipe I, de la Peña A, Aramendia JM, Vanaclocha V. Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine. Br J Dermatol  1997; 136(4): 645-6.
[http://dx.doi.org/10.1111/j.1365-2133.1997.tb02175.x] [PMID:  9155988] 
[92] 
Pérez-Reyes E, Casanova-Lara A, Pérez-Torres E, Córdova J. [Reversal of acute liver failure with N-acetylcysteine and prednisone in a patient with DRESS syndrome: a case report and literature review] Rev Gastroenterol Mex  2014; 79(3): 208-10.
[PMID:  24857421] 
[93] 
Lau G, Kwan C, Chong SM. The 3-week sulphasalazine syndrome strikes again. Forensic Sci Int  2001; 122(2-3): 79-84.
[http://dx.doi.org/10.1016/S0379-0738(01)00476-5] [PMID:  11672959] 
[94] 
Simonart T, Tugendhaft P, Vereecken P, de Dobbeleer G, Heenen M. Hazards of therapy with high doses of N-acetylcysteine for anticonvulsant-induced hypersensitivity syndrome. Br J Dermatol  1998; 138(3): 553.
[http://dx.doi.org/10.1046/j.1365-2133.1998.02150.x] [PMID:  9580826] 
[95] 
Tas S, Simonart T, Heenen M. Angio-oedema caused by high doses of N-acetylcysteine in patients with anticonvulsant hypersensitivity syndrome. Br J Dermatol  2001; 145(5): 856-7.
[http://dx.doi.org/10.1046/j.1365-2133.2001.04428.x] [PMID:  11736926] 
[96] 
Behera SK, Das S, Xavier AS, Selvarajan S.  DRESS syndrome: a
detailed insight. Hosp Pract (1995) 2018; 46(3): 152-62.
[http://dx.doi.org/10.1080/21548331.2018.1451205] 
[97] 
Alexander T, Iglesia E, Park Y, et al. Severe DRESS syndrome managed with therapeutic plasma exchange. Pediatrics  2013; 131(3): e945-9.
[http://dx.doi.org/10.1542/peds.2012-2117] [PMID:  23420918] 
[98] 
Martínez de Lagrán I, Marcos P, Batlle M, Alonso E, Plana A, Tomasa T. Leukapheresis in the management of drug rash with eosinophilia and systemic symptoms syndrome. Med Intensiva  2017; 41(3): 191-3.
[http://dx.doi.org/10.1016/j.medin.2016.02.005] [PMID:  27017438] 
[99] 
Eshki M, Allanore L, Musette P, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol  2009; 145(1): 67-72.
[http://dx.doi.org/10.1001/archderm.145.1.67] [PMID:  19153346] 
[100] 
Ichai P, Laurent-Bellue A, Saliba F, et al. Acute Liver Failure/Injury Related to Drug Reaction With Eosinophilia and Systemic Symptoms: Outcomes and Prognostic Factors. Transplantation  2017; 101(8): 1830-7.
[http://dx.doi.org/10.1097/TP.0000000000001655] [PMID:  28207633] 
[101] 
Thongsri T, Chularojanamontri L, Pichler WJ. Cardiac involvement in DRESS syndrome. Asian Pac J Allergy Immunol  2017; 35(1): 3-10.
[PMID:  27996289] 
[102] 
Chen YC, Chang CY, Cho YT, Chiu HC, Chu CY. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol  2013; 68(3): 459-65.
[http://dx.doi.org/10.1016/j.jaad.2012.08.009] [PMID:  22959230] 
[103] 
Kano Y, Tohyama M, Aihara M, et al. Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR). J Dermatol  2015; 42(3): 276-82.
[http://dx.doi.org/10.1111/1346-8138.12770] [PMID:  25623158] 
[104] 
Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol  2002; 138(8): 1019-24.
[http://dx.doi.org/10.1001/archderm.138.8.1019] [PMID:  12164739] 
[105] 
Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil  2002; 23(2): 87-96.
[http://dx.doi.org/10.1097/00004630-200203000-00004] [PMID:  11882797] 
[106] 
Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol  2000; 136(3): 323-7.
[http://dx.doi.org/10.1001/archderm.136.3.323] [PMID:  10724193] 
[107] 
Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet  2017; 390(10106): 1996-2011.
[http://dx.doi.org/10.1016/S0140-6736(16)30378-6] [PMID:  28476287] 
[108] 
Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. J Plast Reconstr Aesthet Surg  2016; 69(6): e119-53.
[http://dx.doi.org/10.1016/j.bjps.2016.01.034] [PMID:  27287213] 
[109] 
McPherson T, Exton LS, Biswas S, et al. British Association of Dermatologists’ guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018. Br J Dermatol  2019; 181(1): 37-54.
[http://dx.doi.org/10.1111/bjd.17841] [PMID:  30829411] 
[110] 
Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther  2010; 88(1): 60-8.
[http://dx.doi.org/10.1038/clpt.2009.252] [PMID:  20375998] 
[111] 
Barbaud A, Collet E, Milpied B, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol  2013; 168(3): 555-62.
[http://dx.doi.org/10.1111/bjd.12125] [PMID:  23136927] 
[112] 
Lehloenya RJ, Dheda K. Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future. Expert Rev Anti Infect Ther  2012; 10(4): 475-86.
[http://dx.doi.org/10.1586/eri.12.13] [PMID:  22512756] 
[113] 
Lehloenya RJ, Todd G, Wallace J, Ngwanya MR, Muloiwa R, Dheda K. Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug reactions induces systemic reactions in HIV-infected persons. Br J Dermatol  2016; 175(1): 150-6.
[http://dx.doi.org/10.1111/bjd.14492] [PMID:  26918554] 
[114] 
Lehloenya RJ, Todd G, Badri M, Dheda K. Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions. Int J Tuberc Lung Dis  2011; 15(12): 1649-57.
[http://dx.doi.org/10.5588/ijtld.10.0698] [PMID:  22118173] 
[115] 
Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy  2007; 62(12): 1439-44.
[http://dx.doi.org/10.1111/j.1398-9995.2007.01553.x] [PMID:  17983378] 
[116] 
Srinoulprasert Y, Pichler WJ. Enhancement of drug-specific lymphocyte proliferation using CD25(hi)-depleted CD3(+) effector cells. Int Arch Allergy Immunol  2014; 163(3): 198-205.
[http://dx.doi.org/10.1159/000358491] [PMID:  24525750] 
[117] 
Polak ME, Belgi G, McGuire C, et al. In vitro diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions. Br J Dermatol  2013; 168(3): 539-49.
[http://dx.doi.org/10.1111/bjd.12109] [PMID:  23106791] 
[118] 
Porebski G, Pecaric-Petkovic T, Groux-Keller M, Bosak M, Kawabata TT, Pichler WJ. In vitro drug causality assessment in stevens-johnson syndrome - alternatives for lymphocyte transformation test. Clin Exp Allergy  2013; 43(9): 1027-37.
[http://dx.doi.org/10.1111/cea.12145] [PMID:  23957338] 
[119] 
Fujita Y, Yoshioka N, Abe R, et al. Rapid immunochromatographic test for serum granulysin is useful for the prediction of stevens-johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol  2011; 65(1): 65-8.
[http://dx.doi.org/10.1016/j.jaad.2010.04.042] [PMID:  21507517] 
[120] 
Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for stevens-johnson syndrome. Nature  2004; 428(6982): 486.
[http://dx.doi.org/10.1038/428486a] [PMID:  15057820] 
[121] 
Leckband SG, Kelsoe JR, Dunnenberger HM, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther  2013; 94(3): 324-8.
[http://dx.doi.org/10.1038/clpt.2013.103] [PMID:  23695185] 
[122] 
Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in taiwan. N Engl J Med  2011; 364(12): 1126-33.
[http://dx.doi.org/10.1056/NEJMoa1009717] [PMID:  21428768] 
[123] 
Yuan J, Guo S, Hall D, et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of african, asian, and european descent. AIDS  2011; 25(10): 1271-80.
[http://dx.doi.org/10.1097/QAD.0b013e32834779df] [PMID:  21505298] 
[124] 
Dorn JM, Alpern M, McNulty C, Volcheck GW. Sulfonamide Drug Allergy. Curr Allergy Asthma Rep  2018; 18(7): 38.
[http://dx.doi.org/10.1007/s11882-018-0791-9] [PMID:  29876667] 
[125] 
Błaszczyk B, Lasoń W, Czuczwar SJ. Antiepileptic drugs and adverse skin reactions: an update. Pharmacol Rep  2015; 67(3): 426-34.
[http://dx.doi.org/10.1016/j.pharep.2014.11.009] [PMID:  25933949] 
[126] 
Shiny TN, Mahajan VK, Mehta KS, Chauhan PS, Rawat R, Sharma R. Patch testing and cross sensitivity study of adverse cutaneous drug reactions due to anticonvulsants: a preliminary report. World J Methodol  2017; 7(1): 25-32.
[http://dx.doi.org/10.5662/wjm.v7.i1.25] [PMID:  28396847] 
[127] 
Bloch KM, Sills GJ, Pirmohamed M, Alfirevic A. Pharmacogenetics of antiepileptic drug-induced hypersensitivity. Pharmacogenomics  2014; 15(6): 857-68.
[http://dx.doi.org/10.2217/pgs.14.65] [PMID:  24897291] 
[128] 
Romano A, Gaeta F, Arribas Poves MF, Valluzzi RL. Cross-reactivity among beta-lactams. Curr Allergy Asthma Rep  2016; 16(3): 24.
[http://dx.doi.org/10.1007/s11882-016-0594-9] [PMID:  26898316] 
[129] 
Collado-Chagoya R, Hernández-Romero J, Eliosa-Alvarado GA, et al. Tolerance induction to antituberculosis drugs in a patient with stevens-johnson syndrome/toxic epidermal necrolysis overlap. Allergy Rhinol (Providence)  2018; 92152656718783618
[http://dx.doi.org/10.1177/2152656718783618] [PMID:  30083412] 
[130] 
Siripassorn K, Ruxrungtham K, Manosuthi W. Successful drug desensitization in patients with delayed-type allergic reactions to anti-tuberculosis drugs. Int J Infect Dis  2018; 68: 61-8.
[http://dx.doi.org/10.1016/j.ijid.2018.01.006] [PMID:  29410254] 
[131] 
Cho YT, Chu CY. Treatments for severe cutaneous adverse reactions. J Immunol Res  2017; 20171503709
[http://dx.doi.org/10.1155/2017/1503709] [PMID:  29445753] 
[132] 
Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol  2000; 115(2): 149-53.
[http://dx.doi.org/10.1046/j.1523-1747.2000.00061.x] [PMID:  10951229] 
[133] 
Patterson DR, Hofland HW, Espey K, Sharar S. Pain management. Burns  2004; 30(8): A10-5.
[http://dx.doi.org/10.1016/j.burns.2004.08.004] [PMID:  15555783] 
[134] 
Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg  1986; 204(5): 503-12.
[http://dx.doi.org/10.1097/00000658-198611000-00001] [PMID:  3767483] 
[135] 
Kelemen JJ III, Cioffi WG, McManus WF, Mason AD Jr, Pruitt BA Jr. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg  1995; 180(3): 273-8.
[PMID:  7874336] 
[136] 
Lee HY, Dunant A, Sekula P, et al. The role of prior corticosteroid use on the clinical course of stevens-johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. Br J Dermatol  2012; 167(3): 555-62.
[http://dx.doi.org/10.1111/j.1365-2133.2012.11074.x] [PMID:  22639874] 
[137] 
Hirahara K, Kano Y, Sato Y, et al. Methylprednisolone pulse therapy for stevens-johnson syndrome/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers. J Am Acad Dermatol  2013; 69(3): 496-8.
[http://dx.doi.org/10.1016/j.jaad.2013.04.007] [PMID:  23957982] 
[138] 
Zimmermann S, Sekula P, Venhoff M, et al. Systemic immunomodulating therapies for stevens-johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol  2017; 153(6): 514-22.
[http://dx.doi.org/10.1001/jamadermatol.2016.5668] [PMID:  28329382] 
[139] 
Chen J, Wang B, Zeng Y, Xu H. High-dose intravenous immunoglobulins in the treatment of stevens-johnson syndrome and toxic epidermal necrolysis in chinese patients: a retrospective study of 82 cases. Eur J Dermatol  2010; 20(6): 743-7.
[PMID:  20952352] 
[140] 
Firoz BF, Henning JS, Zarzabal LA, Pollock BH. Toxic epidermal necrolysis: five years of treatment experience from a burn unit. J Am Acad Dermatol  2012; 67(4): 630-5.
[http://dx.doi.org/10.1016/j.jaad.2011.12.014] [PMID:  22285617] 
[141] 
Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of stevens-johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol  2008; 58(1): 33-40.
[http://dx.doi.org/10.1016/j.jaad.2007.08.039] [PMID:  17919775] 
[142] 
Micheletti RG, Chiesa-Fuxench Z, Noe MH, et al. stevens-johnson syndrome/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the united states. J Invest Dermatol  2018; 138(11): 2315-21.
[http://dx.doi.org/10.1016/j.jid.2018.04.027] [PMID:  29758282] 
[143] 
Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol  2012; 167(2): 424-32.
[http://dx.doi.org/10.1111/j.1365-2133.2012.10965.x] [PMID:  22458671] 
[144] 
Ye LP, Zhang C, Zhu QX. The effect of intravenous immunoglobulin combined with corticosteroid on the progression of stevens-johnson syndrome and toxic epidermal necrolysis: a meta-analysis. PLoS One  2016; 11(11)e0167120
[http://dx.doi.org/10.1371/journal.pone.0167120] [PMID:  27902746] 
[145] 
Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for stevens-johnson syndrome and toxic epidermal necrolysis. Br J Dermatol  2010; 163(4): 847-53.
[http://dx.doi.org/10.1111/j.1365-2133.2010.09863.x] [PMID:  20500799] 
[146] 
Kirchhof MG, Miliszewski MA, Sikora S, Papp A, Dutz JP. Retrospective review of stevens-johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol  2014; 71(5): 941-7.
[http://dx.doi.org/10.1016/j.jaad.2014.07.016] [PMID:  25087214] 
[147] 
González-Herrada C, Rodríguez-Martín S, Cachafeiro L, et al. Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. J Invest Dermatol  2017; 137(10): 2092-100.
[http://dx.doi.org/10.1016/j.jid.2017.05.022] [PMID:  28634032] 
[148] 
Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet  1998; 352(9140): 1586-9.
[http://dx.doi.org/10.1016/S0140-6736(98)02197-7] [PMID:  9843104] 
[149] 
Paradisi A, Abeni D, Bergamo F, Ricci F, Didona D, Didona B. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol  2014; 71(2): 278-83.
[http://dx.doi.org/10.1016/j.jaad.2014.04.044] [PMID:  24928706] 
[150] 
Wang R, Zhong S, Tu P, Li R, Wang M. Rapid remission of stevens-johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature. Dermatol Ther (Heidelb)  2019; 32(4)e12832
[http://dx.doi.org/10.1111/dth.12832] [PMID:  30659711] 
[151] 
Wang CW, Yang LY, Chen CB, et al. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest  2018; 128(3): 985-96.
[http://dx.doi.org/10.1172/JCI93349] [PMID:  29400697] 
[152] 
de Sica-Chapman A, Williams G, Soni N, Bunker CB. Granulocyte colony-stimulating factor in toxic epidermal necrolysis (TEN) and chelsea & westminster TEN management protocol [corrected]. Br J Dermatol  2010; 162(4): 860-5.
[http://dx.doi.org/10.1111/j.1365-2133.2009.09585.x] [PMID:  19912214] 
[153] 
Narita YM, Hirahara K, Mizukawa Y, Kano Y, Shiohara T. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: is cytokine expression analysis useful in predicting its therapeutic efficacy? J Dermatol  2011; 38(3): 236-45.
[http://dx.doi.org/10.1111/j.1346-8138.2010.01154.x] [PMID:  21342225] 
[154] 
Su SC, Chung WH. Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions. Toxins (Basel)  2014; 6(1): 194-210.
[http://dx.doi.org/10.3390/toxins6010194] [PMID:  24394640] 
[155] 
Han F, Zhang J, Guo Q, et al. Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. J Crit Care  2017; 42: 65-8.
[http://dx.doi.org/10.1016/j.jcrc.2017.07.002] [PMID:  28688239] 
[156] 
Mustafa SS, Ostrov D, Yerly D. Severe cutaneous adverse drug reactions: presentation, risk factors, and management. Curr Allergy Asthma Rep  2018; 18(4): 26.
[http://dx.doi.org/10.1007/s11882-018-0778-6] [PMID:  29574562] 
[157] 
White KD, Abe R, Ardern-Jones M, et al. SJS/TEN 2017: building multidisciplinary networks to drive science and translation. J Allergy Clin Immunol Pract  2018; 6(1): 38-69.
[http://dx.doi.org/10.1016/j.jaip.2017.11.023] [PMID:  29310768] 
[158] 
Merkel PA. Drug-induced vasculitis. Rheum Dis Clin North Am  2001; 27(4): 849-62.
[http://dx.doi.org/10.1016/S0889-857X(05)70239-8] [PMID:  11723768] 
[159] 
Grau RG. Drug-Induced vasculitis: new insights and a changing lineup of suspects. Curr Rheumatol Rep  2015; 17(12): 71.
[http://dx.doi.org/10.1007/s11926-015-0545-9] [PMID:  26503355] 
[160] 
Wiik A. Drug-induced vasculitis. Curr Opin Rheumatol  2008; 20(1): 35-9.
[http://dx.doi.org/10.1097/BOR.0b013e3282f1331f] [PMID:  18281855] 
[161] 
Radic M, Kaplan MJ. Jumbled NETs promote vasculitis. Arthritis Rheum  2012; 64(11): 3498-501.
[http://dx.doi.org/10.1002/art.34615] [PMID:  22777662] 
[162] 
Demoly P, Adkinson NF, Brockow K, et al. International consensus on drug allergy. Allergy  2014; 69(4): 420-37.
[http://dx.doi.org/10.1111/all.12350] [PMID:  24697291] 
[163] 
Costa DAM, Seque CA, Enokihara MMSS, Porro AM. Acute generalized exanthematous pustulosis: a case series of 13 patients in Brazil. J Eur Acad Dermatol Venereol  2019; 33(2): e52-5.
[http://dx.doi.org/10.1111/jdv.15175] [PMID:  29992639] 
[164] 
Ropars N, Darrieux L, Tisseau L, Safa G. Acute generalized exanthematous pustulosis associated with primary epstein-barr virus infection. JAAD Case Rep  2014; 1(1): 9-11.
[http://dx.doi.org/10.1016/j.jdcr.2014.09.004] [PMID:  27075126] 
[165] 
Roujeau JC, Bioulac-Sage P, Bourseau C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol  1991; 127(9): 1333-8.
[http://dx.doi.org/10.1001/archderm.1991.01680080069004] [PMID:  1832534] 
[166] 
Haro-Gabaldón V, Sánchez-Sánchez-Vizcaino J, Ruiz-Avila P, Gutiérrez-Fernández J, Linares J, Naranjo-Sintes R. Acute generalized exanthematous pustulosis with cytomegalovirus infection. Int J Dermatol  1996; 35(10): 735-7.
[http://dx.doi.org/10.1111/j.1365-4362.1996.tb00653.x] [PMID:  8891829] 
[167] 
Navarini AA, Simpson MA, Borradori L, Yawalkar N, Schlapbach C. Homozygous missense mutation in IL36RN in generalized pustular dermatosis with intraoral involvement compatible with both AGEP and generalized pustular psoriasis. JAMA Dermatol  2015; 151(4): 452-3.
[http://dx.doi.org/10.1001/jamadermatol.2014.3848] [PMID:  25427108] 
[168] 
Navarini AA, Valeyrie-Allanore L, Setta-Kaffetzi N, et al. Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Invest Dermatol  2013; 133(7): 1904-7.
[http://dx.doi.org/10.1038/jid.2013.44] [PMID:  23358093] 
[169] 
Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol  2007; 157(5): 989-96.
[http://dx.doi.org/10.1111/j.1365-2133.2007.08156.x] [PMID:  17854366] 
[170] 
Stern RS. Clinical practice. Exanthematous drug eruptions. N Engl J Med  2012; 366(26): 2492-501.
[http://dx.doi.org/10.1056/NEJMcp1104080] [PMID:  22738099] 
[171] 
Feldmeyer L, Heidemeyer K, Yawalkar N. Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy. Int J Mol Sci  2016; 17(8)e1214
[http://dx.doi.org/10.3390/ijms17081214] [PMID:  27472323] 
[172] 
Ingen-Housz-Oro S, Hotz C, Valeyrie-Allanore L, et al. Acute generalized exanthematous pustulosis: a retrospective audit of practice between 1994 and 2011 at a single centre. Br J Dermatol  2015; 172(5): 1455-7.
[http://dx.doi.org/10.1111/bjd.13540] [PMID:  25399843] 
[173] 
Kley C, Murer C, Maul JT, Meier B, Anzengruber F, Navarini AA. Rapid involution of pustules during topical steroid treatment of acute generalized exanthematous pustulosis. Case Rep Dermatol  2017; 9(1): 135-9.
[http://dx.doi.org/10.1159/000471842] [PMID:  28559812] 
[174] 
Kostopoulos TC, Krishna SM, Brinster NK, Ortega-Loayza AG. Acute generalized exanthematous pustulosis: atypical presentations and outcomes. J Eur Acad Dermatol Venereol  2015; 29(2): 209-14.
[http://dx.doi.org/10.1111/jdv.12721] [PMID:  25201706] 
[175] 
Dibek Misirlioglu E, Guvenir H, Bahceci S, et al. Severe cutaneous adverse drug reactions in pediatric patients: a multicenter study. J Allergy Clin Immunol Pract  2017; 5(3): 757-63.
[http://dx.doi.org/10.1016/j.jaip.2017.02.013] [PMID:  28351788] 
[176] 
Mercogliano C, Khan M, Lin C, Mohanty E, Zimmerman R. AGEP overlap induced by hydroxychloroquine: a case report and literature review. J Community Hosp Intern Med Perspect  2018; 8(6): 360-2.
[http://dx.doi.org/10.1080/20009666.2018.1547089] [PMID:  30559945] 
[177] 
van Hattem S, Beerthuizen GI, Kardaun SH. Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features: does overlap between AGEP and TEN exist? Clinical report and review of the literature. Br J Dermatol  2014; 171(6): 1539-45.
[http://dx.doi.org/10.1111/bjd.13152] [PMID:  24888401] 
[178] 
Kaya A, Yıldız S, Balkan II, Eyvazov H, Bavunoglu I, Mert A. Acute generalized exanthematous pustulosis after ceftriaxone use resembling sepsis. J Infect Chemother  2012; 18(1): 112-4.
[http://dx.doi.org/10.1007/s10156-011-0297-z] [PMID:  21912916] 
[179] 
Lateef A, Tan KB, Lau TC. Acute generalized exanthematous pustulosis and toxic epidermal necrolysis induced by hydroxychloroquine. Clin Rheumatol  2009; 28(12): 1449-52.
[http://dx.doi.org/10.1007/s10067-009-1262-4] [PMID:  19727917] 
[180] 
Kiyohara T, Sawai T, Ido H, Kumakiri M. Toxic epidermal necrolysis with some features of acute generalized exanthematous pustulosis. Acta Derm Venereol  2013; 93(2): 212-4.
[http://dx.doi.org/10.2340/00015555-1438] [PMID:  22930254] 
[181] 
Byerly FL, Nelson KC, Granko RP, Morrell DS, Cairns BA. Valdecoxib-associated acute generalized exanthematous pustulosis. Burns  2005; 31(3): 383-7.
[http://dx.doi.org/10.1016/j.burns.2004.10.017] [PMID:  15774300] 
[182] 
Goh TK, Pang SM, Thirumoorthy T, Goh SG. Acute generalised exanthematous pustulosis and toxic epidermal necrolysis induced by carbamazepine. Singapore Med J  2008; 49(6): 507-10.
[PMID:  18581028] 
[183] 
Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol  2015; 73(5): 843-8.
[http://dx.doi.org/10.1016/j.jaad.2015.07.017] [PMID:  26354880] 
[184] 
Rosen A, Del Paggio JC, Chan B, Abu-Abed S, Rawls M, Ellis AK. Acute generalized exanthematous pustulosis with multisystem manifestations: pinpoint pustules and purulent lakes. Ann Allergy Asthma Immunol  2018; 120(1): 92-4.
[http://dx.doi.org/10.1016/j.anai.2017.09.077] [PMID:  29273137] 
[185] 
Lee HY, Chou D, Pang SM, Thirumoorthy T. Acute generalized exanthematous pustulosis: analysis of cases managed in a tertiary hospital in singapore. Int J Dermatol  2010; 49(5): 507-12.
[http://dx.doi.org/10.1111/j.1365-4632.2010.04313.x] [PMID:  20534083] 
[186] 
Teo WL, Pang SM, Koh HY. Allopurinol hypersensitivity syndrome with acute generalized exanthematous pustulosis manifestations. Cutan Ocul Toxicol  2011; 30(3): 243-4.
[http://dx.doi.org/10.3109/15569527.2011.554481] [PMID:  21345152] 
[187] 
Matsuda H, Saito K, Takayanagi Y, et al. Pustular-type drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms due to carbamazepine with systemic muscle involvement. J Dermatol  2013; 40(2): 118-22.
[http://dx.doi.org/10.1111/1346-8138.12028] [PMID:  23216243] 
[188] 
Son CH, Lee CU, Roh MS, Lee SK, Kim KH, Yang DK. Acute generalized exanthematous pustulosis as a manifestation of carbamazepine hypersensitivity syndrome. J Investig Allergol Clin Immunol  2008; 18(6): 461-4.
[PMID:  19123438] 
[189] 
Yalçın B, Çakmak S, Yıldırım B. Successful treatment of hydroxychloroquine-induced recalcitrant acute generalized exanthematous pustulosis with cyclosporine: case report and literature review. Ann Dermatol  2015; 27(4): 431-4.
[http://dx.doi.org/10.5021/ad.2015.27.4.431] [PMID:  26273160] 
[190] 
Sadighha A. Etanercept in the treatment of a patient with acute generalized exanthematous pustulosis/toxic epidermal necrolysis: definition of a new model based on translational research. Int J Dermatol  2009; 48(8): 913-4.
[http://dx.doi.org/10.1111/j.1365-4632.2008.04020.x] [PMID:  19659879] 
[191] 
Chighizola CB, Ong VH, Meroni PL. The use of cyclosporine a in rheumatology: a 2016 comprehensive review. Clin Rev Allergy Immunol  2017; 52(3): 401-23.
[http://dx.doi.org/10.1007/s12016-016-8582-3] [PMID:  27515671] 
[192] 
Moreno-Arrones OM, Carrillo-Gijon R, Sendagorta E, Rios-Buceta L. Acute generalized exanthematous pustulosis simulating stevens-johnson syndrome/toxic epidermal necrolysis associated with the use of vismodegib. JAAD Case Rep  2018; 4(2): 123-5.
[http://dx.doi.org/10.1016/j.jdcr.2017.08.001] [PMID:  29387760] 
[193] 
Krishna S, Ortega-Loayza A, Malakouti N, Brinster N. A rapidly progressive and fatal case of atypical acute generalized exanthematous pustulosis. J Am Acad Dermatol  2014; 71(3): e89-90.
[http://dx.doi.org/10.1016/j.jaad.2014.03.007] [PMID:  25128141] 
[194] 
Cho YT, Lin JW, Chen YC, et al. Generalized bullous fixed drug eruption is distinct from stevens-johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. J Am Acad Dermatol  2014; 70(3): 539-48.
[http://dx.doi.org/10.1016/j.jaad.2013.11.015] [PMID:  24388722] 
[195] 
Lipowicz S, Sekula P, Ingen-Housz-Oro S, et al. Prognosis of generalized bullous fixed drug eruption: comparison with stevens-johnson syndrome and toxic epidermal necrolysis. Br J Dermatol  2013; 168(4): 726-32.
[http://dx.doi.org/10.1111/bjd.12133] [PMID:  23413807] 
[196] 
Bataille M, Vonarx M, Vermersch-Langlin A. Illustration of diagnostic and prognostic difficulties during the early stages of generalized bullous fixed drug eruptions. Eur J Dermatol  2017; 27(1): 86-8.
[http://dx.doi.org/10.1684/ejd.2016.2884] [PMID:  27748265] 
[197] 
Morelli JG, Tay YK, Rogers M, Halbert A, Krafchik B, Weston WL. Fixed drug eruptions in children. J Pediatr  1999; 134(3): 365-7.
[http://dx.doi.org/10.1016/S0022-3476(99)70472-5] [PMID:  10064679] 
[198] 
Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol  2008; 128(1): 35-44.
[http://dx.doi.org/10.1038/sj.jid.5701033] [PMID:  17805350] 
[199] 
Sekula P, Liss Y, Davidovici B, et al. Evaluation of SCORTEN on a cohort of patients with stevens-johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res  2011; 32(2): 237-45.
[http://dx.doi.org/10.1097/BCR.0b013e31820aafbc] [PMID:  21228709] 
[200] 
Tavares Almeida F, Caldas R, André Oliveira Á, Pardal J, Pereira T, Brito C. Generalized bullous fixed drug eruption caused by ibuprofen. Contact Dermat  2019; 80(4): 238-9.
[http://dx.doi.org/10.1111/cod.13176] [PMID:  30430598] 
[201] 
Mitre V, Applebaum DS, Albahrani Y, Hsu S. Generalized bullous fixed drug eruption imitating toxic epidermal necrolysis: a case report and literature review. Dermatol Online J  2017; 23(7): 13030.
[PMID:  29469697] 
[202] 
Özkaya E. Changing trends in inducer drugs of fixed drug eruption: a 20-year cross-sectional study from turkey. J Dtsch Dermatol Ges  2018; 16(4): 474-6.
[http://dx.doi.org/10.1111/ddg.13468] [PMID:  29512939] 
[203] 
Jain A, Gupta N. Multifocal bullous fixed drug erruption due to phenytoin: a lesson learned! J Clin Diagn Res  2015; 9(12): OD04-5.
[http://dx.doi.org/10.7860/JCDR/2015/15464.6908] [PMID:  26816935] 
[204] 
Özkaya E, Kutlay A. Suppositories for fever as a major risk for phenobarbital-induced fixed drug eruption in children. J Eur Acad Dermatol Venereol  2017; 31(10): e443-4.
[http://dx.doi.org/10.1111/jdv.14261] [PMID:  28380244] 
[205] 
Byrd RC, Mournighan KJ, Baca-Atlas M, Helton MR, Sun NZ, Siegel MB. Generalized bullous fixed-drug eruption secondary to the influenza vaccine. JAAD Case Rep  2018; 4(9): 953-5.
[http://dx.doi.org/10.1016/j.jdcr.2018.07.013] [PMID:  30364778] 
[206] 
Beniwal R, Gupta LK, Khare AK, Mittal A, Mehta S, Balai M. Cyclosporine in generalized bullous-fixed drug eruption. Indian J Dermatol  2018; 63(5): 432-3.
[http://dx.doi.org/10.4103/ijd.IJD_458_17] [PMID:  30210171] 
[207] 
Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol  2009; 9(4): 316-21.
[http://dx.doi.org/10.1097/ACI.0b013e32832cda4c] [PMID:  19474709] 
[208] 
Malviya N, Cyrus N, Vandergriff T, Mauskar M. Generalized bullous fixed drug eruption treated with cyclosporine. Dermatol
Online J 2017; 23(2): pii: 13030/qt5zw8d8vs 
[PMID: 28329494] 
[209] 
Flowers H, Brodell R, Brents M, Wyatt JP. Fixed drug eruptions: presentation, diagnosis, and management. South Med J  2014; 107(11): 724-7.
[http://dx.doi.org/10.14423/SMJ.0000000000000195] [PMID:  25365443] 
[210] 
Warrington R, Silviu-Dan F, Wong T. Drug allergy. Allergy Asthma Clin Immunol  2018; 14(Suppl. 2): 60.
[http://dx.doi.org/10.1186/s13223-018-0289-y] [PMID:  30275849] 
[211] 
Silverstein AM. Clemens freiherr von pirquet: explaining immune complex disease in 1906. Nat Immunol  2000; 1(6): 453-5.
[http://dx.doi.org/10.1038/82691] [PMID:  11101860] 
[212] 
de Silva HA, Ryan NM, de Silva HJ. Adverse reactions to snake antivenom, and their prevention and treatment. Br J Clin Pharmacol  2016; 81(3): 446-52.
[http://dx.doi.org/10.1111/bcp.12739] [PMID:  26256124] 
[213] 
Knowles SR, Shear NH. Recognition and management of severe cutaneous drug reactions. Dermatol Clin  2007; 25(2): 245-53.
[http://dx.doi.org/10.1016/j.det.2007.01.011] [PMID:  17430761] 
[214] 
Yorulmaz A, Akın F, Sert A, Ağır MA, Yılmaz R, Arslan Ş. Demographic and clinical characteristics of patients with serum sickness-like reaction. Clin Rheumatol  2018; 37(5): 1389-94.
[http://dx.doi.org/10.1007/s10067-017-3777-4] [PMID:  28795234] 
[215] 
King BA, Geelhoed GC. Adverse skin and joint reactions associated with oral antibiotics in children: the role of cefaclor in serum sickness-like reactions. J Paediatr Child Health  2003; 39(9): 677-81.
[http://dx.doi.org/10.1046/j.1440-1754.2003.00267.x] [PMID:  14629499] 
[216] 
Gomes ER, Brockow K, Kuyucu S, et al. Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug Allergy Interest Group. Allergy  2016; 71(2): 149-61.
[http://dx.doi.org/10.1111/all.12774] [PMID:  26416157] 
[217] 
Vermeire S, Van Assche G, Rutgeerts P. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract Res Clin Gastroenterol  2009; 23(1): 101-12.
[http://dx.doi.org/10.1016/j.bpg.2008.12.005] [PMID:  19258190] 
[218] 
Heckbert SR, Stryker WS, Coltin KL, Manson JE, Platt R. Serum sickness in children after antibiotic exposure: estimates of occurrence and morbidity in a health maintenance organization population. Am J Epidemiol  1990; 132(2): 336-42.
[http://dx.doi.org/10.1093/oxfordjournals.aje.a115663] [PMID:  2115293] 
[219] 
Wong JT, Long A. Rituximab hypersensitivity: evaluation, desensitization, and potential mechanisms. J Allergy Clin Immunol Pract  2017; 5(6): 1564-71.
[http://dx.doi.org/10.1016/j.jaip.2017.08.004] [PMID:  29122155] 
[220] 
Segal AR, Doherty KM, Leggott J, Zlotoff B. Cutaneous reactions to drugs in children. Pediatrics  2007; 120(4): e1082-96.
[http://dx.doi.org/10.1542/peds.2005-2321] [PMID:  17908729] 
[221] 
Colton RL, Amir J, Mimouni M, Zeharia A. Serum sickness-like reaction associated with griseofulvin. Ann Pharmacother  2004; 38(4): 609-11.
[http://dx.doi.org/10.1345/aph.1D291] [PMID:  14982981] 
[222] 
Parshuram CS, Phillips RJ, Nash MC. Serum sickness in a paediatric emergency department: the role of cefaclor. J Paediatr Child Health  1999; 35(2): 223-4.
[PMID:  10365368] 
[223] 
Patterson-Fortin J, Harris CM, Niranjan-Azadi A, Melia M. Serum sickness-like reaction after the treatment of cellulitis with amoxicillin/clavulanate. BMJ Case Rep 2016.
[224] 
Ko JH, Chung WH. Serum sickness. Lancet  2013; 381(9862)e1
[http://dx.doi.org/10.1016/S0140-6736(11)60314-0] [PMID:  22884753] 
[225] 
Bayraktar F, Akinci B, Demirkan F, et al. Serum sickness-like reactions associated with type III insulin allergy responding to plasmapheresis. Diabet Med  2009; 26(6): 659-60.
[http://dx.doi.org/10.1111/j.1464-5491.2009.02733.x] [PMID:  19538244] 
Rights & Permissions Print Cite
Article Metrics
49
5
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1381612825666191106115556	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286
Current Pharmaceutical Design

An Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions

Abstract Play Pause

Related Journals

Related Books

Related Articles

Abstract
